Aug 16 (Reuters) - Seagen said on Wednesday its cancer therapy in combination with Roche's Kadcyla helped control disease progression in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4,495 INR | +2.56% | +4.19% | 2.41B | ||
2,737 PTS | -0.81% | +0.23% | - | ||
232.8 CHF | -0.70% | +2.24% | 208B | ||
1st Jan change | Capi. | |
---|---|---|
+44.48% | 55.07B | |
+43.96% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |